Baader Bank Aktiengesellschaft Purchases 7,328 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Baader Bank Aktiengesellschaft lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 208.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,844 shares of the biopharmaceutical company's stock after acquiring an additional 7,328 shares during the period. Baader Bank Aktiengesellschaft's holdings in Gilead Sciences were worth $1,002,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the business. Foster & Motley Inc. raised its position in shares of Gilead Sciences by 80.4% in the 4th quarter. Foster & Motley Inc. now owns 10,587 shares of the biopharmaceutical company's stock worth $978,000 after acquiring an additional 4,718 shares in the last quarter. Swedbank AB raised its position in shares of Gilead Sciences by 2.7% in the 4th quarter. Swedbank AB now owns 2,101,969 shares of the biopharmaceutical company's stock worth $194,159,000 after acquiring an additional 54,360 shares in the last quarter. Strategic Blueprint LLC raised its position in shares of Gilead Sciences by 7.5% in the 4th quarter. Strategic Blueprint LLC now owns 2,750 shares of the biopharmaceutical company's stock worth $254,000 after acquiring an additional 192 shares in the last quarter. Asset Dedication LLC raised its position in shares of Gilead Sciences by 43.3% in the 4th quarter. Asset Dedication LLC now owns 6,421 shares of the biopharmaceutical company's stock worth $593,000 after acquiring an additional 1,940 shares in the last quarter. Finally, Twelve Points Wealth Management LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth about $611,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Performance

Gilead Sciences stock traded up $1.23 during trading on Thursday, hitting $96.82. The stock had a trading volume of 2,094,775 shares, compared to its average volume of 6,542,193. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The stock's 50 day moving average is $92.14 and its two-hundred day moving average is $85.51. The stock has a market cap of $120.66 billion, a price-to-earnings ratio of 1,074.60, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the prior year, the business earned $2.29 earnings per share. Gilead Sciences's revenue for the quarter was up 7.0% on a year-over-year basis. As a group, analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares of the company's stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Merdad Parsey sold 25,590 shares of the business's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock valued at $42,130,461 in the last 90 days. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Wells Fargo & Company boosted their target price on Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Bank of America reaffirmed a "buy" rating and issued a $109.00 target price on shares of Gilead Sciences in a research report on Tuesday, December 10th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $84.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. Wolfe Research assumed coverage on Gilead Sciences in a research report on Friday, November 15th. They issued an "outperform" rating and a $110.00 target price for the company. Finally, Mizuho lifted their price target on Gilead Sciences from $90.00 to $100.00 and gave the company an "outperform" rating in a research note on Thursday, November 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.